Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis

Efficacy of Intra-articular Injection of Combined Hyaluronic Acid and Platelet-rich Plasma in Knee Degenerative Joint Disease

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03211650

Enrollment

174

Registered

2017-07-07

Start date

2016-10-14

Completion date

2021-03-27

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

The purpose of this study is to evaluate the efficacy of intra-articular injections of combined hyaluronic acid and platelet-rich plasma in knee degenerative joint disease in improving joint function and reducing pain.

Interventions

DRUGhyaluronic Acid + platelet-rich plasma

Intra-articular injections of hyaluronic acid combined with platelet-rich plasma

DRUGhyaluronic acid

Intra-articular injections of hyaluronic acid

DRUGplatelet-rich plasma

Intra-articular injections of platelet-rich plasma

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Knee pain for 4 months; * Knee degenerative sign evaluated with X-ray with a Kellgren-Lawrence grade inferior to 3; * Patients able to understand the study conditions and willing to participate for its entire duration; * Patients who signed written informed consent.

Exclusion criteria

* Severe knee osteoarthritis of grade 4; * Diabetes mellitus; * Rheumatoid arthritis; * Ongoing malignancies; * Certified allergic reactions towards the administered drugs ; * Malalignment of mechanical axis of the lower limb (varus \> 10 °, valgus \> 10 °); * Coagulopathies; * Severe cardiovascular diseases; * Ongoing infections; * Immunodepression; * Anticoagulants or anti-platelet agents; * Haemoglobin \< 11 g/dl; * Platelet count \< 150,000/mm\^3 * Drug addiction; * Alcoholism; * Psychiatric disease; * Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame	Description
WOMAC score	6 months after the first intra-articular injection	Comparison of WOMAC total score among three treatment arms

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026